Navigation Links
A new chemotherapeutic target for hepatocellular carcinoma
Date:10/25/2007

Hepatocellular carcinoma (HCC) is a major health problem worldwide. Currently, the only chance for obtaining a cure in patients with HCC is by either a surgical resection or liver transplantation. However, many HCCs with scattered tumors cannot be operated on. In such patients, effective alternative therapies need to be discovered in order to treat patients in the early stages of this disease.

An article to be published on 28 October in the World Journal of Gastroenterology proposes a new target for therapy. A study was conducted by Dr. Satoshi Mamori, of Jikei University, in which he evaluated tumor biopsies in order to confirm the diagnosis of HCC.

The immunohistochemical expression of survivin in liver tumor specimens obtained from 17 patients was studied. In addition, to determine the survivin expression in response to anti-cancer drugs in early stage HCC, the survivin expression was determined after treating HCC cells with anti-cancer drugs under hypoxic culture conditions.

Survivin is a member of a family of inhibitors of apoptosis protein (IAP), which has been implicated in both the control of cell division and the inhibition of apoptosis. Survivin is selectively expressed in most common human neoplasms and it also appears to be involved in tumor cell resistance to some anticancer agents and ionizing radiation. Several preclinical studies have demonstrated a down-regulation of the survivin expression/function by the use of anti-sense oligonucleotide, dominant negative mutants, ribozymes, small interfering RNAs and cyclin-dependent kinase inhibitors to increase the rate of apoptosis, while also reducing the tumor growth potential and sensitized tumor cells to various chemotherapeutic drugs and -irradiation using both in vitro and in vivo models of various types of human tumors.

The results and conclusions demonstrated survivin protein to be expressed in 64.7% of the cells in early HCC specimens (median). In early stage HCC with a tumor size > 10 mm, the expression rate ranged for 67.7 to 83.7%. Moreover, the survivin protein concentration in HCC cells increased with a combination of hypoxia and anti cancer drugs. With TACE, the conditions of hypoxia are maintained by embolisation over a long period of time. Therefore, this study suggests that survivin could be used as a potential useful therapeutic target for early HCC.


'/>"/>

Contact: You-De Chang
y.d.chang@wjgnet.com
0086-108-538-1892
World Journal of Gastroenterology
Source:Eurekalert

Related medicine news :

1. Cytokine IL6 as a New Chemotherapeutic Target for Ras-driven Cancers
2. Feeding channel created by malaria parasite - a new target for malaria treatments
3. In Search Of A New Drug To Target Cholesterol
4. Enzyme may be target for obesity drugs
5. Target for obesity treatment
6. Scios Inc. targets drug giants in arthritis war
7. Pharmaceutical companies are targeting patients
8. New target for antidiabetic agents identified
9. Gel Offers A More Targeted Approach
10. In Search Of A New Drug To Target Cholesterol
11. Target of diabetes type 1 identified
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... , ... Center for Autism and Related Disorders (CARD) Portland today announced plans ... (ASD) and other developmental disabilities. The group, which is being launched with the help ... opportunity to share stories and advice, seek help, and continue their education on how ...
(Date:12/2/2016)... PA (PRWEB) , ... December 02, 2016 , ... With ... struggling through rehabilitation of an injury, patients must find the one that works for ... his pain, he created a machine that worked and decided to share it with ...
(Date:12/2/2016)... ... December 02, 2016 , ... More than half of American teens report ... parents report speaking with their child about sex related topics, less than 60 percent ... is proud to announce the launch of its second edition of the “Sexual Wellness” ...
(Date:12/2/2016)... ... 02, 2016 , ... The PAINWeekEnd Regional Conference will be ... in Honolulu, offering local frontline clinicians the opportunity to extend their certified continuing ... for supplemental training related to pain management has surged dramatically in recent years, ...
(Date:12/2/2016)... ... December 02, 2016 , ... Rijuven Corp launches rejiva ( http://www.rejiva.com ), ... night. No other wearable health technology on the market can deliver all that rejiva ... more meaningful insights about their health than the usual heart rate and steps taken”, ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , December 2, 2016 bioLytical Laboratories, ein Weltführer ... bei den Mitgliedern des Apothekenbundes von Kenia eingeführt. ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) ...
(Date:12/2/2016)... , Dec. 2, 2016   CytoSorbents Corporation ... commercializing its European Union approved CytoSorb ® cytokine ... surgery patients worldwide, announced that Dr. Phillip Chan ... 9th Annual LD Micro Main Event investor conference ... at the Luxe Sunset Boulevard Hotel in ...
(Date:12/2/2016)... 1, 2016  Today, Simpson Healthcare Executives, a global ... being selected as winners of multiple awards at the ... at the PLATINUM level, Blue Zones Menu at the ... GOLD Level, and our proprietary 3ConneX Platform at the ... Executives, we are excited to showcase our new Platinum ...
Breaking Medicine Technology: